- Home
- CLVT vs RARE Comparison
CLVT vs RARE Comparison
Compare CLVT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- RARE
- Stock Information
- Founded
- CLVT 2016
- RARE 2010
- Country
- CLVT United Kingdom
- RARE United States
- Employees
- CLVT N/A
- RARE N/A
- Industry
- CLVT EDP Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CLVT Technology
- RARE Health Care
- Exchange
- CLVT Nasdaq
- RARE Nasdaq
- Market Cap
- CLVT 2.8B
- RARE 2.6B
- IPO Year
- CLVT N/A
- RARE 2014
- Fundamental
- Price
- CLVT $4.29
- RARE $30.31
- Analyst Decision
- CLVT Hold
- RARE Strong Buy
- Analyst Count
- CLVT 5
- RARE 14
- Target Price
- CLVT $4.83
- RARE $86.64
- AVG Volume (30 Days)
- CLVT 3.8M
- RARE 1.4M
- Earning Date
- CLVT 11-05-2025
- RARE 11-04-2025
- Dividend Yield
- CLVT N/A
- RARE N/A
- EPS Growth
- CLVT N/A
- RARE N/A
- EPS
- CLVT N/A
- RARE N/A
- Revenue
- CLVT $2,500,300,000.00
- RARE $610,159,000.00
- Revenue This Year
- CLVT N/A
- RARE $19.72
- Revenue Next Year
- CLVT N/A
- RARE $23.29
- P/E Ratio
- CLVT N/A
- RARE N/A
- Revenue Growth
- CLVT N/A
- RARE 26.77
- 52 Week Low
- CLVT $3.04
- RARE $25.81
- 52 Week High
- CLVT $7.15
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- CLVT 49.62
- RARE 49.05
- Support Level
- CLVT $4.11
- RARE $31.22
- Resistance Level
- CLVT $4.54
- RARE $31.80
- Average True Range (ATR)
- CLVT 0.14
- RARE 0.93
- MACD
- CLVT -0.01
- RARE 0.07
- Stochastic Oscillator
- CLVT 40.70
- RARE 35.88
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.